Figure 2
From: Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment
Novel A1656D mutation in the SCN5A gene. (A) The sequencing analysis revealed an alanine to aspartic acid mutation at 1656 site in the SCN5A gene (A1656D). (B) The schematic topology of Nav1.5 protein. The A1656D mutation (red circle) was located at the intracellular region between segment 4 and 5 of ___domain 4. (C) The amino acid sequence alignment showing conservation of Ala1656 (red arrow) of SCN5A in multiple species.
